Regulatory flexibility can make continuous improvement possible.
Tim Schofield
Advertisement
Tim Schofield is the director of US regulatory affairs at GlaxoSmithKline
Articles by Tim Schofield
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3Published: January 1st 2010 | Updated:
Quality by Design for Biotechnology Products—Part 2Published: December 1st 2009 | Updated:
Quality by Design for Biotechnology Products—Part 1Published: November 1st 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
$1.8M RedHill Deal Highlights Growing Worldwide Focus on H. pylori Treatment Access
5
